Company intelligence / Profile preview

Rhino Therapeutics

Wilmington, Delaware, USArhinotherapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Developing siRNA-based drugs to activate horizontal basal cells (HBCs) and drive olfactory epithelium repair. Currently conducting studies to establish optimal siRNA sequences, doses, and exposure durations, with testing in mouse models and xenotransplantation of human HBCs into immunocompromised rats.

Therapeutic areas: Neurology
Modalities: siRNA-based drugsregenerative therapies
Industry: Biotech

Partnerships

Tufts University School of Medicine

Beyond the preview

Go deeper on Rhino Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rhino Therapeutics.

Explore the full profile